查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1869686

疼痛管理药物市场规模、份额和趋势分析报告：按药物类别、适应症、分销管道、地区和细分市场预测（2025-2033 年）

Pain Management Drugs Market Size, Share & Trends Analysis Report By Drug Class, By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

疼痛管理药物市场摘要

2024年全球疼痛管理药物市场规模估计为788.4亿美元，预计2033年将达到1,159.2亿美元。

预计从 2025 年到 2033 年，全球疼痛管理药物市场将以 4.38% 的复合年增长率成长。人口老化和生活方式相关因素导致慢性疼痛疾病盛行率上升，推动了全球疼痛管理药物市场的成长。

关节炎、癌症相关疼痛、腰背部疾病、神经病变疼痛和术后疼痛的日益普遍，推动了对有效药物介入的需求。肌肉骨骼和神经系统疾病负担的加重，使得需要长期疼痛治疗的患者群体不断扩大。医疗机构正在采用先进的疼痛管理方法，以提高患者的生活品质并减轻医疗负担。此外，人们越来越认识到疼痛是一种可治疗的临床疾病，这促使疼痛的早期诊断和治疗。全球外科手术数量的增加也导致止痛药和鸦片类药物的消费量增加，凸显了针对性强、多方面的疼痛管理疗法的必要性。

非阿片类镇痛药和新型药物递送技术的持续创新正进一步推动市场扩张。例如，2025年1月，《时代》杂誌报道称，美国食品药物管理局（FDA）核准了由Vertex Pharmaceuticals公司以“Journavx”为商品名销售的舒泽替啶（suzetridine），这是20多年来首个获批的新型非阿片类镇痛药。舒泽替啶是一种50毫克的口服锭剂，每日服用两次，其作用标靶是疼痛神经元特异性的Nav1.8钠通道，从而避免了阿片类药物的成瘾性。在拇趾滑液囊炎手术和腹部整形术后患者的临床试验中，舒泽替啶组分别有83%和61%的参与者报告疼痛减轻30%或更多，而安慰剂组的相应比例分别为68%和48%。这些结果表明，舒泽替啶可能是治疗急性疼痛的一种比鸦片类药物更安全的选择。製药公司也致力于开发更安全的配方，缓释性和经皮製剂的进步正在提高疗效、便利性和患者依从性。

监管审查持续影响市场趋势。例如，2025年3月12日，英国药品和保健产品监管局（MHRA）和药品委员会（CHM）发布了一份详细报告，宣布由于安全隐患，包括持续性术后阿片类药物使用（PPOU）和阿片类药物引起的呼吸功能障碍（OIVI），所有缓释性阿片类药物製剂均不再用于术后镇痛。 PPOU发生率在接受长效阿片类药物治疗的患者为2%至44%，在先前使用过该药物的患者中高达60%。 OIVI的发生率介于0.4%至41%之间。针对这些发现，MHRA建议仅使用速效阿片类药物进行短期术后镇痛治疗，并鼓励采用小容量包装以减少过度处方。总体而言，非成瘾性镇痛药、个人化治疗、数位监测工具和扩大医疗保健服务范围的研究和开发进展，正在推动全球疼痛管理市场的持续成长。

目录

第一章调查方法和范围

第二章执行摘要

第三章 疼痛管理药物市场变数、趋势与范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 定价分析

第四章 疼痛管理药物市场：依药物类别进行业务分析

  • 2024 年及 2033 年市占率
  • 细分仪表板
  • 按药物类别分類的市场规模、预测和趋势分析，2021-2033年
  • NSAIDs
  • 阿片类药物
  • 麻醉剂
  • 抗忧郁症
  • 抗惊厥药
  • 其他的

第五章 疼痛管理药物市场：按适应症分類的业务分析

  • 2024 年及 2033 年市占率
  • 细分仪表板
  • 市场规模、预测与趋势分析（按指标，2021-2033 年）
  • 急性疼痛（术后、创伤相关、肌肉骨骼疼痛）
  • 慢性肌肉骨骼疼痛/骨关节炎/下背痛
  • 神经病变疼痛（糖尿病神经病变、带状疱疹后遗症神经痛、纤维肌痛）
  • 偏头痛（急性期和预防期）
  • 癌症疼痛
  • 手术/住院治疗后引起的疼痛（短期）
  • 其他的

第六章：疼痛管理药物市场：按分销管道分類的业务分析

  • 2024 年及 2033 年市占率
  • 细分仪表板
  • 按分销管道分類的市场规模、预测和趋势分析，2021-2033年
  • 网路药房
  • 零售药房
  • 医院药房

第七章：疼痛管理药物市场：区域估算与趋势分析

  • 2024 年及 2033 年市占率分析
  • 市场仪錶板
  • 2021-2033年各地区市场规模及预测趋势分析
  • 北美洲
    • 按国家/地区划分，2021-2033 年
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争情势

  • 参与者概览
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/上市公司
    • Teva Pharmaceutical
    • Pfizer
    • Abbott
    • Mallinckrodt Pharmaceuticals
    • Endo International
    • GlaxoSmithKline
    • AstraZeneca
    • Depomed
    • Merck
    • Novartis
Product Code: GVR-4-68040-779-0

Pain Management Drugs Market Summary

The global pain management drugs market size was estimated at USD 78.84 billion in 2024 and is projected to reach USD 115.92 billion by 2033, growing at a CAGR of 4.38% from 2025 to 2033. The rising prevalence of chronic pain conditions across aging and lifestyle-affected populations drives the growth of the global pain management drugs market.

Increasing cases of arthritis, cancer-related pain, lower back disorders, neuropathic pain, and post-surgical discomfort have intensified the demand for effective pharmacological interventions. The growing burden of musculoskeletal and neurological disorders has expanded the patient pool requiring long-term pain therapy. Healthcare providers are adopting advanced pain management approaches to enhance quality of life and reduce healthcare burden. In addition, the growing awareness of pain as a treatable clinical condition has supported early diagnosis and treatment. The rising number of surgical procedures globally further contributes to the higher consumption of analgesics and opioids, strengthening the need for targeted and multimodal pain management therapies.

The market expansion is further supported by continuous innovation in non-opioid pain medications and novel drug delivery technologies. For instance, in January 2025, TIME reported that the U.S. Food and Drug Administration (FDA) approved suzetrigine, marketed as Journavx by Vertex Pharmaceuticals, as the first new class of non-opioid pain medication in over 20 years. Suzetrigine is a 50 mg oral tablet taken twice daily and targets the Nav1.8 sodium channel, specific to pain neurons, thereby avoiding the addictive potential of opioids. In clinical trials involving patients recovering from bunionectomy and abdominoplasty surgeries, 83% and 61% of participants taking suzetrigine, respectively, reported at least a 30% reduction in pain, compared to 68% and 48% in the placebo groups. These results suggest that suzetrigine may offer a safer alternative to opioids for managing acute pain. Pharmaceutical companies also focus on developing safer formulations, while advancements in extended-release and transdermal drugs improve efficacy, convenience, and patient adherence.

Regulatory oversight continues to shape market trends. For instance, on March 12, 2025, the UK Medicines and Healthcare products Regulatory Agency (MHRA) and the Commission on Human Medicines (CHM) published a report detailing the removal of the post-operative pain indication from all modified-release opioids due to safety concerns, including persistent post-operative opioid use (PPOU) and opioid-induced ventilatory impairment (OIVI). PPOU occurred in 2% to 44% of patients treated with prolonged-release opioids, rising to 60% in those previously using these opioids, while OIVI incidence ranged from 0.4% to 41%. Consequently, the MHRA recommended that only immediate-release opioids be prescribed for short-term post-operative pain and encouraged smaller pack sizes to reduce over-prescription. Overall, growing R&D in non-addictive analgesics, personalized therapies, digital monitoring tools, and expanded healthcare access is fueling the sustained growth of the pain management drugs market globally.

Global Pain Management Drugs Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pain management drugs market report based on drug class, indication, distribution channel and region:

  • Drug Class Outlook (Revenue, USD Million, 2021 - 2033)
  • NSAIDs
  • Opioids
  • Anesthetics
  • Antidepressants
  • Anticonvulsants
  • Others
  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Acute Pain (Postoperative, Injury-Related, Musculoskeletal)
  • Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain
  • Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia)
  • Migraine (Acute & Preventive)
  • Cancer Pain
  • Post-Surgical / Hospital-Based Procedural Pain (short duration)
  • Others
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Online Pharmacy
  • Retail Pharmacy
  • Hospital Pharmacy
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Pain Management Drugs Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Pricing Analysis

Chapter 4. Pain Management Drugs Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Million)
  • 4.4. NSAIDs
    • 4.4.1. NSAIDs Market, 2021 - 2033 (USD Million)
  • 4.5. Opioids
    • 4.5.1. Opioids Market, 2021 - 2033 (USD Million)
  • 4.6. Anesthetics
    • 4.6.1. Anesthetics Market, 2021 - 2033 (USD Million)
  • 4.7. Antidepressants
    • 4.7.1. Antidepressants Market, 2021 - 2033 (USD Million)
  • 4.8. Anticonvulsants
    • 4.8.1. Anticonvulsants Market, 2021 - 2033 (USD Million)
  • 4.9. Others
    • 4.9.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Pain Management Drugs Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 5.4. Acute Pain (Postoperative, Injury-Related, Musculoskeletal)
    • 5.4.1. Acute Pain (Postoperative, Injury-Related, Musculoskeletal) Market, 2021 - 2033 (USD Million)
  • 5.5. Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain
    • 5.5.1. Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain Market, 2021 - 2033 (USD Million)
  • 5.6. Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia)
    • 5.6.1. Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia) Market, 2021 - 2033 (USD Million)
  • 5.7. Migraine (Acute & Preventive)
    • 5.7.1. Migraine (Acute & Preventive) Market, 2021 - 2033 (USD Million)
  • 5.8. Cancer Pain
    • 5.8.1. Cancer Pain Market, 2021 - 2033 (USD Million)
  • 5.9. Post-Surgical / Hospital-Based Procedural Pain (short duration)
    • 5.9.1. Post-Surgical / Hospital-Based Procedural Pain (short duration) Market, 2021 - 2033 (USD Million)
  • 5.10. Others
    • 5.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Pain Management Drugs Market: Distribution Channel Business Analysis

  • 6.1. Distribution Channel Market Share, 2024 & 2033
  • 6.2. Distribution Channel Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 6.4. Online Pharmacy
    • 6.4.1. Online Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.5. Retail Pharmacy
    • 6.5.1. Retail Pharmacy Market, 2021 - 2033 (USD Million)
  • 6.6. Hospital Pharmacy
    • 6.6.1. Hospital Pharmacy Market, 2021 - 2033 (USD Million)

Chapter 7. Pain Management Drugs Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Pain Management Drugs Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Target Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Target Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. U.S. Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Target Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Target Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. Uk Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Target Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Target Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Target Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Target Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Target Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Target Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Target Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Target Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Target Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Target Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Target Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Target Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Target Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Target Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Japan Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Target Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. China Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Target Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Target Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Target Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Target Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Pain Management Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Teva Pharmaceutical
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Pfizer
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Abbott
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Mallinckrodt Pharmaceuticals
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Endo International
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. GlaxoSmithKline
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. AstraZeneca
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Depomed
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Merck
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Novartis
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global pain management drugs market, by region, 2021 - 2033 (USD Million)
  • Table 4 Global pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 5 Global pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 6 Global pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 7 North America pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 8 North America pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 9 North America pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 10 North America pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 11 U.S. pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 12 U.S. pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 13 U.S. pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 14 Canada pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 15 Canada pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 16 Canada pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 17 Mexico pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 18 Mexico pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 19 Mexico pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 20 Europe pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 21 Europe pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 22 Europe pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 23 Europe pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 24 UK pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 25 UK pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 26 UK pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 27 Germany pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 28 Germany pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 29 Germany pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 30 France pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 31 France pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 32 France pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 33 Italy pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 34 Italy pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 35 Italy pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 36 Spain pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 37 Spain pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 38 Spain pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 39 Norway pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 40 Norway pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 41 Norway pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 42 Denmark pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 43 Denmark pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 44 Denmark pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 45 Sweden pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 46 Sweden pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 47 Sweden pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 48 Asia Pacific pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 49 Asia Pacific pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 50 Asia Pacific pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 51 Asia Pacific pain management drugs market, by distribution channel, 2021 - 2033 (USD
  • Table 52 Japan pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 53 Japan pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 54 Japan pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 55 China pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 56 China pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 57 China pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 58 India pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 59 India pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 60 India pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 61 Australia pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 62 Australia pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 63 Australia pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 64 South Korea pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 65 South Korea pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 66 South Korea pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 67 Thailand pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 68 Thailand pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 69 Thailand pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 70 Latin America pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 71 Latin America pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 72 Latin America pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 73 Latin America pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 74 Brazil pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 75 Brazil pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 76 Brazil pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 77 Argentina pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 78 Argentina pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 79 Argentina pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 80 Middle East & Africa Pain management drugs market, by country, 2021 - 2033 (USD Million)
  • Table 81 Middle East & Africa pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 82 Middle East & Africa pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 83 Middle East & Africa pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 84 South Africa pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 85 South Africa pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 86 South Africa pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 87 Saudi Arabia pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 88 Saudi Arabia pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 89 Saudi Arabia pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 90 UAE pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 91 UAE pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 92 UAE pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)
  • Table 93 Kuwait pain management drugs market, by drug class, 2021 - 2033 (USD Million)
  • Table 94 Kuwait pain management drugs market, by indication, 2021 - 2033 (USD Million)
  • Table 95 Kuwait pain management drugs market, by distribution channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Pain management drugs market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and drug class outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Pain management drugs market dynamics
  • Fig. 12 Pain management drugs market: Porter's five forces analysis
  • Fig. 13 Pain management drugs market: PESTLE analysis
  • Fig. 14 Drug class market, 2021 - 2033 (USD Million)
  • Fig. 15 NSAIDs market, 2021 - 2033 (USD Million)
  • Fig. 16 Opioids market, 2021 - 2033 (USD Million)
  • Fig. 17 Anesthetics market, 2021 - 2033 (USD Million)
  • Fig. 18 Antidepressants market, 2021 - 2033 (USD Million)
  • Fig. 19 Anticonvulsants market, 2021 - 2033 (USD Million)
  • Fig. 20 Others market, 2021 - 2033 (USD Million)
  • Fig. 21 Indication market, 2021 - 2033 (USD Million)
  • Fig. 22 Acute Pain (Postoperative, Injury-Related, Musculoskeletal) market, 2021 - 2033 (USD Million)
  • Fig. 23 Chronic Musculoskeletal Pain / Osteoarthritis / Low Back Pain market, 2021 - 2033 (USD Million)
  • Fig. 24 Neuropathic Pain (Diabetic Neuropathy, Postherpetic Neuralgia, Fibromyalgia) market, 2021 - 2033 (USD Million)
  • Fig. 25 Migraine (Acute & Preventive) market, 2021 - 2033 (USD Million)
  • Fig. 26 Cancer Pain market, 2021 - 2033 (USD Million)
  • Fig. 27 Post-Surgical / Hospital-Based Procedural Pain (short duration) market, 2021 - 2033 (USD Million)
  • Fig. 28 Others market, 2021 - 2033 (USD Million)
  • Fig. 29 Distribution channel market, 2021 - 2033 (USD Million)
  • Fig. 30 Online pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 31 Retail pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 32 Hospital pharmacy market, 2021 - 2033 (USD Million)
  • Fig. 33 Pain management drugs market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 North America pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 36 U.S. country dynamics
  • Fig. 37 U.S. pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 38 Canada country dynamics
  • Fig. 39 Canada pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 40 Mexico country dynamics
  • Fig. 41 Mexico pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 42 Europe pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 43 UK country dynamics
  • Fig. 44 UK pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 45 Germany country dynamics
  • Fig. 46 Germany pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 47 France country dynamics
  • Fig. 48 France pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 49 Italy country dynamics
  • Fig. 50 Italy pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 51 Spain country dynamics
  • Fig. 52 Spain pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 53 Norway country dynamics
  • Fig. 54 Norway pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 55 Sweden country dynamics
  • Fig. 56 Sweden pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 57 Denmark country dynamics
  • Fig. 58 Denmark pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 59 Asia Pacific pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 60 Japan country dynamics
  • Fig. 61 Japan pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 62 China country dynamics
  • Fig. 63 China pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 64 India country dynamics
  • Fig. 65 India pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 66 Australia country dynamics
  • Fig. 67 Australia pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 68 South Korea country dynamics
  • Fig. 69 South Korea pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 70 Thailand country dynamics
  • Fig. 71 Thailand pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 72 Latin America pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 73 Brazil country dynamics
  • Fig. 74 Brazil pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 75 Argentina country dynamics
  • Fig. 76 Argentina pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 77 MEA pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 78 South Africa country dynamics
  • Fig. 79 South Africa pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 80 Saudi Arabia country dynamics
  • Fig. 81 Saudi Arabia pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 82 UAE country dynamics
  • Fig. 83 UAE pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 84 Kuwait country dynamics
  • Fig. 85 Kuwait pain management drugs market, 2021 - 2033 (USD Million)
  • Fig. 86 Company categorization
  • Fig. 87 Company market position analysis
  • Fig. 88 Strategic framework